Turnkey Contract Research & Testing Services tailored to local regulatory submission requirements under the Directorate General of Drug Administration (DGDA).
Understanding the structural shift from formulation manufacturing to sophisticated R&D, drug discovery, and botanical standardization in South Asia.
The Bangladeshi pharmaceutical industry satisfies over 98% of its domestic medicine demand and exports to more than 150 nations. However, with Bangladesh preparing to graduate from Least Developed Country (LDC) status, the World Trade Organization’s TRIPS flexibility for intellectual property exemptions will phase out. Local manufacturers in Dhaka, Gazipur, and Narayanganj are aggressively transitioning from simple generic drug formulation to advanced Active Pharmaceutical Ingredient (API) synthesis, novel drug delivery systems (NDDS), and comprehensive pre-clinical testing to defend market dominance.
The Directorate General of Drug Administration (DGDA) of Bangladesh has implemented stricter regulatory guidelines regarding drug safety, bioequivalence, and herbal formulation purity. As the Ayurvedic and Unani Medicine Act 2023 gains enforcement traction, botanical extract producers and traditional medicine manufacturers require scientific, cell-based in vitro validation, standardized cytotoxicity screens, and batch-to-batch assay verification to gain regulatory registration and access international export channels.
Information Gain Insight: Sourcing high-end OEM In Vitro testing services allows Bangladeshi pharmaceutical companies to bypass the steep capital expenditure (CapEx) of building GLP-certified cell biology laboratories, while gaining immediate access to advanced testing platforms like Flow Cytometry, High-Content Screening (HCS), and LC-MS/MS analytical validation.
Unlocking operational agility, reproducible scientific evidence, and global regulatory compliance.
Offshore OEM CRO contract research accelerates preclinical timelines by 40-60%. Standardized assay protocols for cell viability, enzymatic target screening, and gene expression profiling are executed under strict SOPs, yielding verified raw data within weeks.
Eliminate multi-million dollar investments in cleanroom biological containment, liquid handling robotics, and biosafety cabinet infrastructures. Procurement teams shift fixed overhead into flexible operational expenditure (OpEx).
Every in vitro evaluation report contains full methodology details, calibration curves, statistical power calculations, and raw microplate readings suitable for submission to DGDA, US FDA, EMA, or GCC health agencies.
Comprehensive biological assay frameworks designed for synthetic pharmaceuticals, APIs, natural extracts, and cosmetics.
Quantitative toxicological assays using mammalian cell lines (HepG2, Caco-2, Vero, A549, HEK293). Methodologies include colorimetric MTT/XTT assays, LDH release for membrane integrity, and luminescent CellTiter-Glo ATP quantitation to establish IC50 and CC50 values accurately.
Mechanism of Action (MoA) profiling for targeted therapeutic discovery. Includes COX-1/COX-2 cyclooxygenase activity, 5-LOX inhibition, alpha-glucosidase / alpha-amylase (anti-diabetic models), DPPH/ABTS radical scavenging, and tyrosinase enzyme kinetic kinetics.
Intestinal epithelial cell monolayer models to predict human oral absorption, active transport mechanisms, and P-glycoprotein (P-gp) efflux interactions, assisting Bangladeshi formulation chemists in optimizing oral bio-availability.
Salmonella typhimurium bacterial reverse mutation (Ames test) and mammalian cell micronucleus testing according to OECD guidelines (OECD 471 & 473) to verify structural chromosome damage and mutagenic risk prior to animal studies.
LPS-stimulated RAW264.7 macrophage models quantifying nitric oxide (NO) inhibition, TNF-alpha, IL-1beta, and IL-6 cytokine down-regulation via ELISA and multiplex bead-based immunoassays.
Multi-component synergistic assay testing designed specifically for Ayurvedic, Unani, and traditional herbal formulations, correlating chromatographic HPLC chemical fingerprints with biological efficacy assays.
Transitioning from basic 2D cell cultures to AI-integrated predictive screening and microfluidic organ-on-a-chip models.
Standardized automated cytotoxicity, enzyme kinetics, and cell viability microplate assays providing rapid screening for synthetic APIs and natural molecules.
Implementation of 3D multicellular tumor spheroids and primary hepatocyte co-cultures to simulate tissue physiology, drug penetration dynamics, and microenvironmental factors.
Incorporation of dynamic fluid flow Liver-on-a-Chip and Gut-on-a-Chip devices for physiological ADME-Tox modeling, reducing reliance on animal testing.
Combining quantitative structure-activity relationship (QSAR) machine learning models with real-time bio-assay datasets to predict drug target interactions instantly.
Addressing the specific logistical, legal, and operational parameters required by Bangladeshi pharmaceutical manufacturers.
Seamless cold-chain biospecimen transit protocol handling from Hazrat Shahjalal International Airport (Dhaka) to our international GLP facility, ensuring sample preservation at -80°C or dry ice conditions.
Assay workflows utilizing certified non-porcine cell enzymes, recombinant trypsin alternatives, and Halal-compliant growth supplements to ensure market adaptability in Muslim-majority regions.
Strict Non-Disclosure Agreements (NDAs) and clear intellectual property assignment contracts ensure proprietary active molecules and herbal extract formulas remain 100% owned by the client.
Essential guidance for R&D directors, procurement managers, and regulatory officers in Bangladesh.
The DGDA requires verified preclinical toxicity and efficacy data for new drug applications (NDA), API registration, and modern herbal formulations. Our OEM In Vitro test reports adhere to ICH and OECD guidelines, featuring full calibration curves, IC50 analysis, GLP compliance certification, and method validation summaries that directly integrate into section 4 (Nonclinical Study Reports) of the Common Technical Document (CTD) format.
Yes. Many Bangladeshi manufacturers work with complex polyherbal mixtures (Ayurvedic/Unani). We specialize in custom assay protocol development—such as cell-based antioxidant response element (ARE) activation, NF-kB pathway inhibition, or specific enzymatic suppression—standardizing biological potency regardless of seasonal crop variations.
For standard high-throughput in vitro screens (e.g., MTT cytotoxicity, DPPH antioxidant, COX-2 enzyme inhibition), we typically require as little as 10 to 50 milligrams of purified compound, or 1 to 5 grams of crude botanical extract powder or concentrated liquid.
Standard screening assays (such as cytotoxicity IC50 profiling) are completed within 10 to 14 business days following sample receipt and customs verification. Complex multi-target pathways or long-term cell line adaptation protocols typically require 3 to 4 weeks.
We provide full biological material transfer agreement (MTA) documentation and work with specialized cold-chain logistics partners (such as DHL Medical Express or FedEx Clinical Care). Ambient, chilled (4°C), or frozen (-20°C/-80°C with dry ice) conditions are continuously monitored with temp-tale dataloggers throughout transit.
Absolutely. By utilizing our pre-established cell line banks and automated assay platforms, companies avoid the capital investment of expensive instrumentation (e.g., microplate readers, flow cytometers, incubator suites) and specialized cell culture scientist salaries, reducing preclinical testing costs by up to 70%.
Seamlessly bridging laboratory research, active screening, preclinical testing, and OEM/ODM manufacturing.
Partner with an internationally recognized CRO & CDMO leader. Receive custom protocol proposals, GLP assay timelines, and budget estimations tailored for Bangladesh’s pharmaceutical and herbal markets.
Send Inquiry Now